Pharmaceutical Gelatin Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Pharmaceutical Gelatin Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The pharmaceutical gelatin market is expected to grow, with an estimated CAGR of 5.5% over the forecast period (2022-2027).

COVID-19 has a great impact on gelatin production and the supply chain. Lonza, a key player in the capsules segment, has reported that COVID-19 has impacted the demand and supply chain of pharmaceutical capsules. On the other side, gelatin also has found its importance in the COVID-19 treatment. For instance, according to the study titled 'Gelatin Stabilizes Nebulized Proteins in Pulmonary Drug Delivery against COVID-19' in May 2022, the addition of gelatin to the drug delivery significantly stabilizes the proteins and enhances the fractions of active proteins after nebulization, minimizing the medication dosage. Such advantages of gelatin in COVID-19 patient's treatment will lead to increased adoption of pharmaceutical gelatin, driving the market growth.

The factors driving the growth of the pharmaceutical gelatin market include rising demand for pharmaceutical-grade gelatin, increasing burden of chronic disease, rise in geriatric population, growing advancements of gelatin nanoparticles in drug and vaccine, among others.

The rising application of gelatin in cosmetic applications, intrinsic activities, and biomedical applications in wound dressing and wound healing, gene therapy, tissue engineering, implants, and bone substitutes is driving the market growth. For instance, according to the study titled 'Cosmetic, Biomedical and Pharmaceutical Applications of Fish Gelatin/Hydrolysates' in March 2021, pharmaceutical applications has varied applications in manufacturing of capsules, coating of microparticles/oils, coating of tablets, stabilization of emulsions and drug delivery (microspheres, nanospheres, scaffolds, microneedles, and hydrogels). Furthermore, according to the same source, gelatin obtain from fish is immunologically safe, protects from the possibility of transmission of bovine spongiform encephalopathy and foot and mouth diseases, has an economic and environmental benefits, and are suitable for those that practice religious-based food restrictions. Such added advantages of gelatin in pharmaceutical industry will lead to rise in adoption, driving the market growth.

In addition, rise in advancement of gelatin in drug delivery will also drive the market growth of pharmaceutical gelatin over the forecast period. For instance, according to the study titled 'Toxicology of Nanoparticles in Drug Delivery' in November 2021, gelatin is a natural, biodegradable, and biocompatible material that can be used to deliver drugs for tumour therapy, including resveratrol, cycloheximide, and doxorubicin, Due to its low cost, biocompatibility, biodegradability, limited antigenicity, and use in a variety of formulations, gelatin nanoparticles have been proposed as a choice for parenteral formulations. This will lead to adoption of gelatin in parenteral drug delivery systems, driving the market growth.

However, rising trend in veganism and culture restrictions, side effects associated with animal derived gelatin in humans, among others are expected to hinder the market growth.

Key Market TrendsCapsules Segment Holds a Significant Share in the Market Over the Forecast Period

Being gelatin is used as a coating for hard and soft-gel capsules, its wide range of applications drives positive growth of the gelatin market in the pharmaceutical industry. Gelatin is used as an excipient in producing soft gel and hard capsules. Gelatin protects sensitive ingredients from contamination, oxygen, light, and microbial growth.

The factors driving the growth of this capsules segment include the rise in consumption of over-the-counter (OTC) medicines, the rise in chronic diseases, and the rise in initiatives from the key market players for the manufacture of innovative gelatin capsules shells with innovative technologies, among others. For instance, etectRx, Inc., a digital health startup, launched the beginning of a study to track antiretroviral therapy adherence among prescription opioid users living with human immuno virus (HIV). The "MyTPill" trial will evaluate patient adherence using the ID-Cap System which involves a hard gelatin capsule with an embedded ingestible wireless sensor and a wearable reader. Such initiatives will lead to increased adoption of gelatin for the production of hard gelatin capsules (ID-Cap) driving this segment growth.

Furthermore, in August 2021, Advent International acquired a majority ownership interest in Shanxi Guangsheng Medicinal Capsule Co., Ltd (“GS Capsule”), the largest domestic capsule provider in China. GS Capsule produces gelatin capsules for pharmaceutical and healthcare product companies across China and for export to international markets in North America, Europe and Southeast Asia. Such mergers and acquisitions will lead to the implementation of strategies by the key market players in the capsule manufacturing, driving this segment growth.

Therefore, owing to the above mentioned factors, this capsule segment is expected to show a significant growth over the forecast period.

North America Holds a Major Market Share and Expected to do Same in the Forecast Period

The factors responsible for the major share of North America in the pharmaceutical gelatin market include ample availability of raw materials, such as porcine and bovine, the strong foothold of key market players, and developed healthcare infrastructure, among others.

To ensure the safety and effectiveness of the vaccine during storage and transport, gelatin derived from pork is being used as a stabilizer in a vaccine, which is a driving factor for the high demand for pharmaceutical-grade gelatin in the present market, especially in countries, like the United States and Canada, where there is a high prevalence of chronic diseases. Hence, owing to the factors mentioned above, the market is expected to witness significant growth in the future.

The advancements in technology and the rise in the incidence of diseases are driving the factors for pharmaceutical gelatin in North America. For instance, According to the International Diabetes Federation (IDF) updated in November 2021, The North America and Caribbean (NAC) region has the second highest diabetes prevalence among IDF regions at 14%. IDF projects that the number of people with diabetes in the NAC Region will increase by 24% reaching 63 million by 2045. The NAC Region has the second highest number of children and adolescents with type 1 diabetes with a count of 193,000 in total. Such a high prevalence of chronic diseases will lead to increased adoption of medication for diabetes, thereby leading to high adoption of pharmaceutical gelatin by capsule manufacturers, driving the market growth in this region.

Furthermore, rising gelatin capsule manufacturing services in North America is also expected to drive the market growth in this region. For instance, in March 2021, CapsCanada,one of the leading company in capsule technology introduced a new service for the production of liquid-filled hard capsules. The goal of CapsCanada is to support the complete manufacturing process, from product discovery and formulation to full-scale production. Such initiatives will lead to increased adoption of pharmaceutical gelatin for capsule filling in the formulation development, driving the market growth in this region.

In addition, rise in launch of new gelatin brands is also expected to drive the market growth in this region. For instance, in May 2021, GelDAT was launched by Darling Ingredients' Rousselot Brand. It launched X-Pure - GelDAT as an alternative for GelTYR - Gelatin Tyramine by considering the limitations, irreproducibility, and lack of a scalable production process of GelTYR. Such launch of innovative products will further drive the market growth due to rise in adoption to their improved properties.

Therefore, owing to the factors such as rise in chronic diseases, rise in capsule manufacturing services, among others are expected to drive the market growth in this region.

Competitive Landscape

The pharmaceutical gelatin market is moderately competitive, with several players across the world. In terms of market share, few of the major players currently dominate the market. High prevalence of chronic diseases, gelatin being used as gelatin nanoparticles in drug delivery systems and vaccines, many global players are expected to be a part of the pharmaceutical gelatin market over the forecast period. Some of the major players in the market are Darling Ingredients Inc., Nitta Gelatin Inc., Gelita AG, Tessenderlo Group (PB Leiner), Weishardt, Trobas Gelatine BV, Nitta Gelatin, India Gelatine & Chemicals Ltd, among others.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.